ACCC 46TH ANNUAL MEETING & CANCER CENTER BUSINESS SUMMIT

March 4–6, 2020
Washington Hilton, DC

An exclusive gathering where industry insiders, health policy experts, and key influencers in cancer care delivery will explore the convergence of BUSINESS, POLICY, and TECHNOLOGY—and how it impacts your world.

SOLD OUT IN 2019!

SECURE YOUR SEAT BY JANUARY 20 TO SAVE UP TO $125
ACCC-CANCER.ORG/AMCCBS

ANNUAL MEETING PLATINUM SPONSORS

GOLD, SILVER, & BRONZE SPONSORS

CHAMPS Oncology, GenomOncology, Integrated Oncology, LeanTaaS, Navigating Cancer, NeoGenomics Laboratories, Pinnacle Health Consulting, PYA, Roche Diagnostics Corporation, TSK Products, Unlimited Systems, Varian Medical Systems, VMG Health (Confirmed as of 11/21/19)

CO-HOSTS

ACCC
Association of Community Cancer Centers

CCBD GROUP
CANCER CENTER BUSINESS DEVELOPMENT

FOLEY
FOLEY & LARDNER LLP
Those Who Are Navigating, Providing, and Leading Cancer Care

AMCCBS is a thought leadership forum for organizations across the healthcare ecosystem—from health systems, hospital-based cancer programs, and physician group practices, to national healthcare corporations, and industry partners—with the aim of sparking connections, collaboration, and learning in an effort to improve oncology care delivery nationwide.

Armed with information on strategies for bringing more cost-effective cancer delivery to your program or practice, new treatments and technologies, and the latest public policy changes that will affect your livelihood, AMCCBS can help you be better positioned to develop and streamline services, market your program, and keep costs in check. All individuals engaged in cancer care operations should attend—join us!

- Hospital presidents/CEOs/COOs/VPs/trustees
- Operations, development, and finance directors
- Chief medical officers and medical directors
- Oncology clinicians (medical, radiation, surgical, pharmacy)
- Oncology program and practice administrators, managers, and service line executives
- Healthcare consultants, vendors, and suppliers
- Pharmaceutical and biotechnology manufacturers
- Medical information technology specialists
- Government affairs and health policy directors
- Cancer program marketing and public relations professionals

WHO WILL ATTEND

AGENDA-AT-A-GLANCE

WEDNESDAY, MARCH 4
11:00 AM – 6:00 PM  Registration/Customer Service Desk Open
12:00 – 5:00 PM  Radiation Oncology Pre-Conference *R
12:00 – 5:00 PM  Surgical Oncology Pre-Conference *R
5:00 – 6:00 PM  Welcome and Opening Reception in the Exhibit Hall

THURSDAY, MARCH 5
7:00 – 8:00 AM  Breakfast in the Exhibit Hall
8:00 AM – 4:55 PM  General and Breakout Sessions, Networking Breaks, Lunch, and Exhibit Hall
6:00 – 8:00 PM  Dine-Around DC Event (Optional) *R

FRIDAY, MARCH 6
7:00 – 7:45 AM  Breakfast in the Exhibit Hall
7:00 – 8:30 AM  Sponsored Content Sessions
7:45 – 8:30 AM  ACCC House of Delegates Meeting (Open to All)
8:45 AM – 2:00 PM  General Sessions, Networking Breaks, Lunch, and Exhibit Hall

*R = Separate Registration Required
WHAT YOU WILL LEARN

The agenda is designed to provide new ideas and fresh perspectives on how to manage—and capitalize on—the dramatic changes happening in this shifting healthcare landscape.

**GENERAL SESSIONS** provide forward-thinking approaches to forecasting—and navigating—trending topics in oncology business models and operations. The agenda divides into three tracks—each providing strategic insights and forward-thinking solutions within specialized learning environments. These **BREAKOUT SESSIONS** are outstanding opportunities for personalized education and bi-directional conversations, while **CASE STUDIES** offer practical takeaways, “from the field” insights, and effective practices.

**Thursday, March 5**

7:00 – 8:00 AM BREAKFAST IN THE EXHIBIT HALL

8:00 – 8:15 AM AMCCBS WELCOME & KICK-OFF

8:15 – 9:15 AM GENERAL SESSION

**Disruptive Innovations That Could Change the Delivery of Cancer Care**

_Susan Dentzer, Senior Policy Fellow, Duke-Margolis Center for Health Policy_

Respected healthcare policy analyst and thought leader Susan Dentzer will share her vision for the future of cancer care, the technology trends and healthcare delivery platforms on the horizon, and the opportunities—and barriers—to building an effective infrastructure that supports innovation.

As one of the nation’s most respected health and health policy thought leaders, Ms. Dentzer works on health system transformation, biopharmaceutical policy, and other key health policy issues. At the Center, she focuses on research and thought leadership for modernizing the healthcare system through the use of greater virtual care and a reconfigured healthcare workforce; improving health and healthcare in rural areas; and other topics.

9:15 – 10:15 AM GENERAL SESSION

**Federal Healthcare Policy in an Election Year**

Hear about Federal efforts in healthcare that are underway and will likely survive the post-2020 election, and how they might impact the delivery and financing of cancer care. Thought leaders will discuss what Medicare-for-all and other proposed reforms could mean for cancer care delivery and offer insights into the most-up-to-date federal policy and regulation changes and drug pricing efforts.

10:15 – 10:45 AM NETWORKING BREAK IN THE EXHIBIT HALL

**Meet the 2020 AMCCBS Advisory Committee & Task Force**

ACC-CANCER.ORG/AMCCBS-COMMITTEE

“Love the information, case studies, and discussion about collaborative arrangements between community practice settings and other organizations.”

_Sharon K. Steingass, RN, MSN, AOCN, Director, Clinical Operations: James Affiliate/Community Program, Clinical Call Center and JamesLine, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University_
### Thursday, March 5 (continued)

#### 10:45 – 11:30 AM  BREAKOUT SESSIONS

**TRACK 1**

*Seeking Greener Pastures: Motivators and Processes for Change of Practice Setting*
Ronald R. Barkley, MS, JD, President & CEO, Cancer Center Business Development Group
Teri U. Guidi, MBA, FAAMA, President & CEO, Oncology Management Consulting Group
Erich A. Mounce, MSHA, Chief Operating Officer, OneOncology

**TRACK 2**

*Engaging Physician Leaders for the Future of Oncology*
Matthew A. Manning, MD, FASTRO, Interim Chief of Oncology, Cone Health

**TRACK 3**

*Costs and Benefits of Palliative Care in the Hospital, Clinic, and Home*
J. Brian Cassel, PhD, Hematology, Oncology, & Palliative Care Division, Department of Internal Medicine, Virginia Commonwealth University School of Medicine

#### 11:35 AM – 12:20 PM  BREAKOUT SESSIONS

**TRACK 1**

*Preparing for the Value-Based Enterprise: Practical Legal and Valuation Tips for the New Paradigm*
Alan H. Einhorn, Of Counsel, Foley & Lardner LLP
Tynan O. Kugler, Principal, PYA, PC.

**TRACK 2**

*Leveraging APPs to Improve Care Delivery and the Patient Experience*
Jiajoyce R. Conway, DNP, CRNP, AOCNP; Christian Patterson, PA-C; and Chanh Huynh, MD; Cancer Care Associates of York

**TRACK 3**

*Urgent Care for Cancer Patients: Reducing ED Visits and Hospitalizations*
Mike Koroscik, MHA, MBA, Oncology Service Line Executive, Sutter Health

#### 12:20 – 1:20 PM  LUNCH IN THE EXHIBIT HALL

#### 1:20 – 2:05 PM  BREAKOUT SESSIONS

**TRACK 1**

*Expanding Your Horizons: Transactional Issues in Hospital Physician Alignment*
Brad Prechtl, MBA, Chief Executive Officer, Florida Cancer Specialists & Research Institute
Adria E. Warren, Partner, Foley & Lardner LLP

**TRACK 2**

*Telehealth: Opportunities and Challenges in Oncology*
Linda D. Bosserman, MD, FACP, FASCO, Assistant Clinical Professor, City of Hope
Emily H. Wein, Of Counsel, Foley & Lardner LLP

**TRACK 3**

*Lost in Translation: Design Implications for Multidisciplinary Cancer Care*
Michael Lied, Director of Healthcare, GBBN Architects
Angela Mazzi, AIA, FACHA, EDAC, Associate Principal, GBBN Architects
Mark Witte, Executive Director, TriHealth Cancer Institute

---

**Stay Engaged!** Follow ACCC on Twitter @ACCCBuzz, Instagram at accc_cancer, and facebook.com/accccancer for breaking #AMCCBS updates.
<table>
<thead>
<tr>
<th>TRACK 1</th>
<th>TRACK 2</th>
<th>TRACK 3</th>
</tr>
</thead>
</table>
| Role of Private Equity and Sponsors in Oncology  
Vince Kickirillo, CFA, CVA,  
Managing Director, Business Valuation and Transaction Advisory, VMG Healthcare  
Adria E. Warren, Partner, Foley & Lardner LLP | Building and Sustaining a Financially Viable Clinical Trials Program Through Technology  
Carla Balch, MS, Oncology Technology Entrepreneur; Chief Executive Officer, Inteliqeut  
Emily Graham, MS, MBA, Director, Strategic Initiatives, Pfizer Inc.  
Ryan Jones, MBA, Chief Executive Officer, Florence Healthcare | National Evidence-Based Oncology Navigation Metrics Demonstrate Value and Sustainability of Navigation Programs  
Danelle Johnston, MSN, RN, HON ONN-CG, OCN, CNO, Senior Director Strategic Planning & Initiatives, The Lynx Group; AONN+ Co-Principal Study Investigator  
Kelley D. Simpson, MBA, Director and Partner, The Chartis Group, Chartis Oncology Solutions Practice; Study Investigator  
Tricia Strusowski, MS, RN, Consultant, The Chartis Group, Chartis Oncology Solutions Practice; Chair, AONN+ National Metrics Committee, Study Investigator |
| **It was great to speak with other cancer centers who are navigating similar waters. It gives me confidence in our program’s direction and provides additional resources for me to rely on and gather information from.**  
Barbara McFarland, MBA, Administrator, Outpatient Cancer Services, Georgia Regents University Cancer Center | | |

**2:10 – 2:55 PM BREAKOUT SESSIONS**

**TRACK 1**

**Immuno-Oncology in 2020: What We’ve Learned and What’s Ahead**  
Sigrun Hallmeyer, MD, Director, Cancer Institute; Medical Director, Cancer Survivorship Program, Advocate Lutheran General Hospital; Co-Director, PRC Russell Institute for Research and Innovation  
Lee S. Schwartzberg, MD, FACP, Executive Director, The West Cancer Center  
Additional Panelist Speakers TBD

**TRACK 2**

**Disruption in Drug Delivery and Pricing**  
Melody Chang, RPh, MBA, BCOP, Director of Pharmacy Operations, Florida Cancer Specialists & Research Institute  
Marc Earl, PharmD, BCOP, Assistant Director of Pharmacy, Cleveland Clinic  
Jennifer F. Walsh, Public Affairs Director, Foley & Lardner LLP

**TRACK 3**

**Digital Health Revolution**  
Gitesh Patel, Chief Executive Officer, Sargas Pharmaceutical Adherence & Compliance International (MODERATOR)  
Carol Carnell, MBA, RN, Chief Administrative Officer, West Cancer Center  
James Hamrick, MD, Senior Medical Director, Flatiron Health  
Mark Nelson, PharmD, Chief Executive Officer, Northwest Medical Specialties  
Sharang Phadke, Product Manager, Flatiron Health  
Charles Saunders, MD, Chief Executive Officer, Integra Connect  
Nirav R. Shah, MD, MPH, Head Revenue Cycle Operations, Flatiron Health  
Dennis Zoet, Chief Business Development Officer, Cancer & Hematology Centers of Western Michigan

**2:55 – 3:25 PM NETWORKING BREAK**

**3:25 – 4:55 PM BREAKOUT SESSIONS**

**TRACK 1**

**2:10 – 2:55 PM BREAKOUT SESSIONS**

**TRACK 1**

**Business Model Sessions**

**TRACK 2**

**Operational Hot Topics**

**TRACK 3**

**Case Study Explorations**
Friday, March 6

7:00 – 7:45 AM BREAKFAST IN THE EXHIBIT HALL

7:00 – 8:30 AM SPONSORED CONTENT SESSIONS

7:45 – 8:30 AM ACCC HOUSE OF DELEGATES MEETING (OPEN TO ALL)

8:45 – 9:30 AM GENERAL SESSION

“Direct to Patient” Engagement in Oncology—What it is and How to Achieve it

Precision Medicine Accelerator, a program out of the Harvard Business School, co-chaired by Kathy Giusti and Richard G. Hamermesh

What opportunities can a “direct to consumer” bring to oncology? Following a large-scale, pan-oncology market research project, Kraft developed a comprehensive, “direct to patient” road map to help patients navigate their cancer journey, close knowledge gaps, and optimize outcomes. Non-profit provider organizations have overwhelmingly endorsed and are working to roll out the model. Learn what a “direct to patient” model can look like, including practical and operational obstacles and solutions; and other practical tips and lessons learned along the way.

9:30 – 10:15 AM NETWORKING BREAK IN THE EXHIBIT HALL

10:15 – 11:15 AM GENERAL SESSION

Collaborate, Educate, Compensate. Creating a Sustainable Model for Cancer Care Delivery

Al B. Benson III, MD, FACP, Professor of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine

Ali McBride, PharmD, MS, BCOP, Clinical Coordinator, Hematology/Oncology, The University of Arizona Cancer Center, Department of Pharmacy

Additional Panelist Speakers TBD

ACCC launched a national Comprehensive Cancer Care Services Survey in 2019, whose outcomes led to development of a tiered matrix of services that cancer practices and programs of varying sizes and resource levels can adopt. Hear a multidisciplinary panel of experts involved in the development of the matrix address how the provision of these services can elevate patient care and the patient experience; reduce healthcare costs; improve care coordination; identify implementation challenges and opportunities; and outline various avenue for how key services can be covered.

11:15 AM – 12:15 PM GENERAL SESSION

What You Need to Know About Oncology Alternative Payment Models in 2020

Alexis Bortniker, JD, Partner, Foley & Lardner LLP (MODERATOR)

Barbara L. McAneny, MD, FASCO, MACP, Chief Executive Officer, NM Oncology Hematology Consultants; Immediate Past-President, American Medical Association

Anne Hubbard, Director of Health Policy, American Society for Radiation Oncology

Ted Okon, MBA, Executive Director, Community Oncology Alliance

Lalan S. Wilfong, MD, Executive Vice President, Value Based Care and Quality Programs, Texas Oncology; Physician Liaison for Value-Based Care, McKesson Specialty Health (Invited)

An overview and status update of the various Alternative Payment Models (APMs) currently in effect in oncology today, including the segue from the Oncology Care Model (OCM) to CMMI’s proposed Oncology Care First (OCF) Model; the Merit-Based Incentive Payment System (MIPS); the Radiation Oncology (RO) Model; Medicaid-specific APMs; the MASON model (Making Accountable Sustainable Oncology Networks); private payer APM programs, and more. A blue ribbon panel of experts in value-based care and APMs in oncology will offer their perspectives and debate the question: What do oncology practices and cancer programs need to know to thrive in this rapidly evolving APM environment?

12:15 – 1:15 PM GENERAL SESSION

Applied Informatics in Oncology

Debra Patt, MD, MPH, MBA, Vice President, Texas Oncology; Medical Director, McKesson Specialty Health; Editor-in-Chief, ASCO JCO Journal of Clinical Cancer Informatics

Drawing from her decades-long experience in health economics, outcomes research, and clinical informatics, Dr. Patt will share the latest developments and breakthroughs in decision support and predictive analytics in oncology that are improving quality and increasing value in oncology care. Learn practical tips and best practices for the application of multiple integrated data assets to understand cancer outcomes and to move the needle forward in value-based cancer care.

1:15 – 2:00 PM AMCCBS CONCLUDES WITH NETWORKING LUNCH

For the latest meeting updates and registration details, visit ACCC-CANCER.ORG/AMCCBS
SPECIAL EVENTS

RADIATION ONCOLOGY PRE-CONFERENCE

Wednesday, March 4, 12:00 – 5:00 PM

Explore forward-thinking strategies necessary for supporting radiation oncology program viability and innovation. Participate in robust, multidisciplinary discussions that address the critical issues—and opportunities—facing today’s radiation oncology practices and programs.

Cost: Complimentary with your meeting registration. ACCC members can register for this one-day pre-conference for $75; non-ACCC members can attend for $230, which includes one year of ACCC Individual Membership.

SURGICAL ONCOLOGY PRE-CONFERENCE

Wednesday, March 4, 12:00 – 5:00 PM

Through the examination of case studies, we’ll explore the drivers and obstacles, building blocks, costs, and effective practices of a successful surgical oncology program. Participants will have the opportunity to critique, question, and learn from peers who have developed successfully integrated surgical oncology programs.

Cost: Complimentary with your meeting registration. ACCC members can register for this one-day pre-conference for $75; non-ACCC members can attend for $230, which includes one year of ACCC Individual Membership.

Visit ACCC-CANCER.ORG/AMCCBS-Precon for agenda information.

D.C. DINE-AROUND EVENT
(Regular)

Thursday, March 5, 6:00 – 8:00 PM

Washington, D.C. is an exciting and diverse dining destination. Take advantage of this opportunity to experience one of D.C.’s well-regarded restaurants and connect with colleagues. Indicate your interest in participating in this Dutch treat activity during registration. We’ll announce the restaurant selections closer to the meeting date—curated by a leading D.C. food blogger, @beenthereeatenthat.

“During the Surgery Oncology Pre-Conference, I was able to connect with colleagues who had low-dose CT programs. They gave me excellent insight on how to improve my current program that I will bring back to my program leadership.”

Arielle Hollins, MHA, Multidisciplinary Team Manager, Mary Bird Perkins Our Lady of the Lake Cancer Center

Separate Registration is Required for all Annual Meeting Special Events.
ACCC 46TH ANNUAL MEETING & CANCER CENTER BUSINESS SUMMIT
March 4–6, 2020
Washington Hilton, DC

REGISTRATION TYPE | By January 20 | After January 20
--- | --- | ---
ACCC Cancer Program Member | $525 | $650
ACCC Individual Member/Oncology State Society at ACCC Member | $625 | $725
2nd Registrant (Exclusive to ACCC Cancer Program Members)* | $350 | $475
Non-Member Multidisciplinary Care Team Members, Association/Non-Profit/ Patient Advocacy Group Staff | $750 | $850
ACCC Industry Council Member | $850 | $850
Non-Member Industry/Company/ Consultants/Vendors | $1,025 | $1,025

* An ACCC Cancer Program Member who registers for the conference at the full rate ($525 or higher) may register ONE additional person from their cancer program or practice at a discounted rate.

A Group Rate is available to three or more individuals of the same institution. For more information, please email membership@accc-cancer.org.

If you would like to become a member of ACCC to obtain the reduced rates—or are unsure of your membership status—please contact the Membership Department at membership@accc-cancer.org or call 301.984.9496, ext. 267.

ACCC INDUSTRY MEMBERS

Industry Advisory Council
AbbVie
Amgen, Inc.
Astellas
AstraZeneca
Bayer HealthCare Pharmaceuticals
Bristol-Myers Squibb
Celgene Corporation
Eisai, Inc.
Eli Lilly and Company
Genentech, Inc.
GlaxoSmithKline
Jansen Oncology
Merck & Company
Novartis Oncology
Pfizer Oncology
Regeneron
Sanofi
Teva Oncology

Emerging Companies Council
Array Biopharma
BeiGene
Boehringer Ingelheim
Coherus
EMD Serono
Exelixis, Inc.
Incyte Corporation
Ipsen Biopharmaceuticals
Karyopharm
Kite Pharma
MorphoSys
Mylan
Pharmacyclics
Puma Biotechnology, Inc.
Seattle Genetics
Sun Pharma
Taiho Oncology
Takeda Oncology
TerSara
Verastem

Technical Advisory Council
Adaptive Biotherapeutics
Foundation Medicine
Walgreens

The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community. Founded in 1974, ACCC is a powerful network of 25,000 multidisciplinary practitioners from 2,100 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapting its resources to meet the changing needs of the entire oncology care team. For more information, visit accc-cancer.org or call 301.984.9496. Follow us on Facebook, Twitter, and LinkedIn; read our blog, ACCCBuzz; and tune in to our podcast, CANCER BUZZ.